» Articles » PMID: 20353976

Antiphospholipid Antibodies and the Protein C Pathway

Overview
Journal Lupus
Publisher Sage Publications
Specialty Rheumatology
Date 2010 Apr 1
PMID 20353976
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Haemostasis is a delicate balance between procoagulant and anticoagulant processes. In the human body usually anticoagulant mechanisms prevail over procoagulant mechanisms, thereby preventing a prothrombotic state. The antiphospholipid syndrome is an example in which this balance is shifted to a more prothrombotic state due to the presence of antiphospholipid antibodies. One of the most extensively proposed pathogenic mechanisms within the antiphospholipid syndrome is the inhibition of protein C by antiphospholipid antibodies. Antiphospholipid antibodies have been described to have different actions on the protein C pathway, for example decreasing protein C and/or S plasma levels, inducing increased resistance against activated protein C and lowering thrombin levels (resulting in an impaired protein C activation). This review briefly discusses the actions of protein C in human body but mainly focuses on the effects of antiphospholipid antibodies on the protein C pathway that have been described in literature.

Citing Articles

Understanding the difference between type I and type II antiprothrombin antibodies and their effect on activated protein C resistance.

Pozzi N, Pontara E, Kumar S, Pengo V J Thromb Haemost. 2024; 22(10):2935-2938.

PMID: 39029741 PMC: 11567715. DOI: 10.1016/j.jtha.2024.07.005.


How We Interpret Thrombosis with Thrombocytopenia Syndrome?.

Yamada S, Asakura H Int J Mol Sci. 2024; 25(9).

PMID: 38732176 PMC: 11084439. DOI: 10.3390/ijms25094956.


Catastrophic Antiphospholipid Syndrome.

Bitsadze V, Yakubova F, Khizroeva J, Lazarchuk A, Salnikova P, Vorobev A Int J Mol Sci. 2024; 25(1).

PMID: 38203837 PMC: 10779422. DOI: 10.3390/ijms25010668.


Hospitalized patients with positive antiphospholipid antibodies who have low complement levels are at increased risk for death-a retrospective cohort study.

Itelman E, Perelman M, Bivar N, Kent D, Vaisman A, Segal G Lupus. 2023; 32(5):668-674.

PMID: 36951167 PMC: 10155279. DOI: 10.1177/09612033231164091.


Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Yuan W, Guan F Autoimmune Dis. 2022; 2022:3208037.

PMID: 35795725 PMC: 9252713. DOI: 10.1155/2022/3208037.